Ipafricept
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer[1][2][3].
Product Specifications
CAS Number
1391727-24-4
Product Name Alternative
OMP-54F28; FZD8-Fc
UNSPSC
12352203
Target
Wnt
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ipafricept.html
Purity
99.80
Solubility
10 mM in DMSO
Smiles
[Ipafricept]
Molecular Weight
(81.97 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Ogfod1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
